Nā huahana

1. No ka noiʻi ʻana inā hiki i ka adenosine diphosphate (ADP) i loaʻa i ka adenosine ke kāohi i ka platelet aggregation, ʻoi aku ka nui o ke alo o ka P2Y₁₂ antagonist, kahi e pale ʻia ai nā hopena o ka ADP ma ka P2Y₁₂ receptor. peptide ma ka helu platelet i loko o ka platelet-rich plasma (PRP) a me ke koko holoʻokoʻa i mua o ka ADP a me ka P2Y₁₂ antagonists cangrelor, prasugrel active metabolite, a me ticagrelor.Ma ke alo o ka P2Y₁₂ antagonist, preincubation o PRP me ADP inhibited aggregation;Ua hoʻopau ʻia kēia hopena e ka adenosine deaminase.ʻAʻole i hoʻopaʻa ʻia ka hōʻuluʻulu ʻana i loko o ke koko holoʻokoʻa koe wale nō ka hoʻohui ʻia ʻana o dipyridamole e pale i ka lawe ʻana o adenosine i loko o nā erythrocytes.Hoʻopili hou ʻia nā hopena o ADP ma PRP a me ke koko holoʻokoʻa me ka hoʻohana ʻana i ka adenosine a pili pono i nā loli i ka cAMP (i loiloi ʻia e vasodilator-stimulated phosphoprotein phosphorylation).Ua like nā hopena a pau me ka nānā ʻole i ka P2Y₁₂ ant agonist i hoʻohana ʻia. ADP inhibits platelet aggregation i mua o ka P2Y₁₂ antagonist ma o ka hoʻololi ʻana i adenosine.Loaʻa ka pale ʻana i ka PRP akā ʻaʻole i loko o ke koko holoʻokoʻa koe wale nō ke kāohi ʻia ka adenosine uptake.ʻAʻohe o ka P2Y₁₂ antagonists i aʻo hou i nā hopena o ka dipyridamole i nā hoʻokolohua i hana ʻia.

2. Manaʻo ʻia ʻo ADP he agonist platelet nāwaliwali ma muli o nā pane aggregation liʻiliʻi i hoʻoulu ʻia i loko o ka vitro ma nā ʻano physiological o extracellular Ca(2+) [(Ca(2+) )(o)].ʻO ka hoʻohaʻahaʻa ʻana i [Ca(2+) ](o) e hoʻonui i ka hoʻohui ʻana i hoʻāla ʻia e ADP, kahi hopena i manaʻo ʻia no ka hoʻonui ʻana i ka thromboxane A(2).Ua nānā kēia haʻawina i ke kuleana o nā ectonucleotidases i ka [Ca(2+) ](o) -dependence o ka hoʻoulu ʻana o ka platelet.ʻO ka hōʻemi ʻana i ka [Ca(2+) ](o) mai ka millimolar a hiki i ka micromolar pae i hoʻololi ʻia i ka ADP (10 μmol/l) -evoked platelet aggregation mai kahi transient a i ka pane hoʻomau i loko o ka platelet-rich plasma a me ka holoi ʻana.ʻAʻohe hopena i kēia [Ca(2+) ](o) -dependence ka pale ʻana i ka thromboxane A(2) me ka aspirin.ʻO ka paleʻana i ka hoʻohaʻahaʻa ADP i hoʻopau i nāʻokoʻa ma waena o ka haʻahaʻa a me ka physiological [Ca(2+) ](o) i hopena i ka hōʻuluʻulu paʻa a paʻa i nā kūlana ʻelua.Ua hōʻike ʻia nā ana o extracellular ADP i ka emi ʻana o ka hoʻohaʻahaʻa ʻana i ka plasma a me ka apyrase-containin g saline ma ka micromolar i hoʻohālikelike ʻia me ka millimolar [Ca(2+)](o).E like me ka mea i hōʻike mua ʻia, ua hoʻonui ʻia ka thromboxane A(2) hanauna ma ka haʻahaʻa [Ca(2+) ](o), akā kūʻokoʻa kēia i ka hana ectonucleotidase(.) P2Y receptor antagonists cangrelor a me MRS2179 i hōʻike i ka pono o nā mea loaʻa P2Y(12). no ka hui ʻana i hoʻoulu ʻia e ADP, me kahi kuleana liʻiliʻi no P2Y(1).I ka hopena, ʻo Ca(2+) -dependent ectonucleotidase hana he mea nui e hoʻoholo ai i ka nui o ka platelet aggregation i ADP a pono e hoʻomalu ʻia no nā haʻawina o ka hoʻoulu ʻana o ka receptor P2Y.